Ireland
--:--IST
Latest
Budget 2027: €29.1bn for Health, Rare Disease Medicines Pilot Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Budget 2027: €29.1bn for Health, Rare Disease Medicines Pilot Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity
Clinical Trials in the Netherlands / NCT05967091
Active, not recruiting Not applicable

Ryme Medical TLD Pilot Study

NCT05967091 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Ryme Medical, Inc
Phase
Not applicable
Started
2024-03-06
Last updated
2025-08-13

Condition(s) studied

Chronic Obstructive Pulmonary Disease

Investigational drug(s) / intervention(s)

Targeted Lung Denervation

Targeted Lung Denervation: Targeted Lung Denervation (TLD) is a bronchoscopically guided, minimally invasive procedure using the Ryme Medical Lung Denervation System

Study summary

Targeted lung denervation (TLD) with the Ryme Medical Lung Denervation System in patients with chronic obstructive pulmonary disease (COPD) - Ryme Medical TLD Pilot Study

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * Symptomatic chronic obstructive pulmonary disease * ≥40 years of age * Smoking history of at least 10 pack years * Candidate for bronchoscopy in the opinion of the Investigator Key Exclusion Criteria: * Recent COPD exacerbation or respiratory infection * Prior lung intervention with device in place * Pulmonary nodule or malignancy requiring treatment * Current chemotherapy or radiation therapy and/or has received treatment within 6 months * Current smoker, using e-cigarettes or vaping, or taking any inhaled substances not prescribed by a physician * Clinically significant serious or unstable medical conditions (e.g., heart disease requiring treatment, uncontrolled diabetes) * Pregnant, nursing, or intent to become pregnant during study duration

Primary outcome measure(s)

  • Device Safety — 30 Days
    Serious adverse events associated with the Ryme Medical Lung Denervation System

Trial sites (7)

FacilityCityRegionStatus
Melbourne Health - The Royal Melbourne Hospital Melbourne Australia
Macquarie University Sydney Australia
Karl Landsteiner Institute for Lung Research Vienna Austria
Rigshospitalet Copenhagen Denmark
Healthycore Tbilisi Georgia
University of Groningen Medical Center Groningen Netherlands
Royal Brompton London United Kingdom

Other trials for the same condition

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. Recruiting
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Active, not recruiting
Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05967091 on ClinicalTrials.gov ↗ ← All trials in the Netherlands